Recordati rare diseases | Radio Compass News | PharmaCompass.com

Grow Your Pharma Business Digitally

X

Market Place

Sourcing support

Sourcing Support

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

All News Recordati Rare Diseases

Recordati 2024 Preliminary Results: Revenue +12.4%, EBITDA +12.5%

13 Feb 2025 //

GLOBENEWSWIRE

Recordati Rare Diseases, Pedea 5 mg/ml solution for injection, EL(22)A/45

27 Oct 2022 //

GOVUK

Recordati Announce Publication of Outcomes From PIII LINC 3 Study of Isturisa

31 Aug 2022 //

BUSINESSWIRE

Phase III LINC 3 Study Says ISTURISA Shows Improvement in Cushing’s Disease

13 May 2022 //

BUSINESSWIRE

Recordati Rare Diseases Announces William Ludlam As New Chief Medical Officer

25 Aug 2021 //

BUSINESSWIRE

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study

23 Mar 2021 //

BUSINESSWIRE

Recordati: Positive Results From the Phase III LINC-4 Study at the Endocrine

23 Mar 2021 //

BUSINESSWIRE

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study

22 Mar 2021 //

BUSINESSWIRE

Recordati Rare Diseases Announces Availability of CYSTADROPS in the U.S.

15 Sep 2020 //

BIOSPACE

U.S. FDA Approves CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%

25 Aug 2020 //

PRNEWSWIRE

CVC revs up rare disease ambitions with $3.5B Recordati buy

05 Jul 2018 //

FIERCE PHARMA

Recordati Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection)

05 Jul 2017 //

PR NEWSWIRE